PPT-Mechanisms of resistance to EGFR

TKI s and related treatment strategies Rafal Dziadziuszko Medical University of Gdańsk Poland 16th European Congress Perspectives in Lung Cancer Torino. Endocrinology laboratory. Department of Zoology. Kalyani. University. Kalyani. , West Bengal. India. Epidermal growth factor (EGF) promotes ovarian . steroidogenesis. and epidermal growth factor receptor (EGFR) . carcinoma. - . new. . biomarkers. Rafal. . Dziadziuszko. Medical. . University. of Gdańsk, Poland. Molecular. . aberrations. . in . lung. . adenocarcinoma. Driving. . molecular. . events. :. Cell Free Circulating . DNA in Detecting EGFR Mutations Present in Tumor . Tissue. S. Das. 1. , L. Bazhenova. 2. , V. Singh. 3. , L. Arnold. 3. , V. Alexiadis. 3. , T. Watanaskul. 3. ; . 1. Internal Medicine, Division of Hematology-Oncology, University of California San Diego, La Jolla, CA/United States of America, . Le Chevalier, . MD. The Role of Translational Research . in . NSCLC. Outline of Talk. The importance of translational research in improving treatment of NSCLC. Key remaining unmet needs. Overview of promising approaches/agents in the future treatment of NSCLC . Increases . Safety Window in Preclinical Studies. Bryan A. Irving Ph.D. . Vice President, Cancer Immunology @CytomX Therapeutics, Inc.. Presenter Disclosure Information. The following relationships exist related to this presentation:. RTK’s--How do they work?. EGFR signaling and . ras. MAP k. inase cascades. PI3K, PKB, . PLC. g. PTPs (Protein Tyrosine Phosphatases). Epidermal growth factor. Neurotrophic growth factor (NGF) isolated from mouse. The New EPOC Study. Randomi. ze. Surgery. Oxaliplatin. or . Irinotecan. w. ith FP . + . cetuximab. Surgery. 6 cycles . (3months). N. =268 . patients. Oxaliplatin. or . Irinotecan. w. ith FP . + . MD. The Evolving Treatment Landscape in NSCLC: Congress Updates. Outline of Talk. Provide a brief overview of current advances in the treatment of NSCLC. EGFR-targeted agents . ALK-EML4 targeted agents . Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Practitioner. Abramson Cancer Center. University of Pennsylvania Health System. Disclosures of Conflicts of Interest. Ms. Eaby-Sandy, MSN, CRNP, OCN. ®. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Copyright © 2015 by Saunders, an imprint of Elsevier Inc.. Introduction. Antimicrobial agents. Chemical compounds to kill or suppress microorganisms. Antibiotics. Natural, semisynthetic, or synthetic molecules used to treat or prevent disease . Komal. . Pareek. 1. Key Terms. Antibiotic = A drug that kills or inhibits the growth of microorganisms. Resistant = Somewhat arbitrary designation that implies that an antimicrobial will not inhibit bacterial growth at clinically achievable concentrations. Third Lecture . 2022. Assist. Prof. Mohammed AboKsour. It is the ability of microbes to grow and multiply in the presence of antimicrobial agent that would normally kill them or limit their growth. The concentration of drug at the site of infection must inhibit the organism and . Ana Rima. Lung Cancer: Incidence and Mortality. New cases in 2013: 228,190. 40% with stage IV disease at presentation (~ 90,000). ~ 160,000 deaths in 2012, comparable to prostate, pancreas, breast, and colon cancer combined.